Skip to content
CancerIndex

Country

United States

Cancer incidence and mortality for United States as published by the source registry: per site group, per year and sex, with age-standardized rates where the source provides them. Population statistics describe groups, never individuals.

ISO 3166-1
USA · US
WHO region
WHO Region of the Americas
Population
not seeded — CancerIndex shows only rates and counts published by the source
Years covered
1999–2024
Cancer entities
36
Estimate types
observed

Summary

2016 · Male · all ages

Totals across all cancer sites are shown only when the source publishes an all-sites row. Otherwise the per-site figures below stand on their own; CancerIndex never sums site groups (definitions overlap between sources).

  • Deathshighest site group:Malignant Lung Neoplasm80,775countcdc-uscsProvenance
    Source
    U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
    Dataset
    U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
    Version
    USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
    Retrieved
    Sep 8, 2026
    Layer
    normalized (units and labels harmonized; values unchanged)
    Evidence
    registry
    License
    US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
    Run
    ING-CDCUSCS-20260908-000001
    Open at source     Observed26 site groups
  • New caseshighest site group:Malignant Prostate Neoplasm207,883countcdc-uscsProvenance
    Source
    U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
    Dataset
    U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
    Version
    USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
    Retrieved
    Sep 8, 2026
    Layer
    normalized (units and labels harmonized; values unchanged)
    Evidence
    registry
    License
    US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
    Run
    ING-CDCUSCS-20260908-000001
    Open at source     Observed27 site groups
  • Mortality rate (age-standardized)highest site group:Malignant Lung Neoplasm47.5per 100,000cdc-uscsProvenance
    Source
    U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
    Dataset
    U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
    Version
    USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
    Retrieved
    Sep 8, 2026
    Layer
    normalized (units and labels harmonized; values unchanged)
    Evidence
    registry
    License
    US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
    Run
    ING-CDCUSCS-20260908-000001
    Open at source     Observed26 site groups
  • Incidence rate (age-standardized)highest site group:Malignant Prostate Neoplasm109.9per 100,000cdc-uscsProvenance
    Source
    U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
    Dataset
    U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
    Version
    USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
    Retrieved
    Sep 8, 2026
    Layer
    normalized (units and labels harmonized; values unchanged)
    Evidence
    registry
    License
    US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
    Run
    ING-CDCUSCS-20260908-000001
    Open at source     Observed27 site groups

No all-sites total in source for this scope — per-site figures below; no national total is computed.

Top cancers

By deaths

2016 · Male · all ages · 26 site groups

#CancerDeaths (count)95% CITypeRank in scopeSite definitionSource
1Malignant Lung NeoplasmCancer80,775—observed#1 of 26USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349)cdc-uscsObserved
2Malignant Prostate NeoplasmCancer30,370—observed#2 of 26USCS "Prostate" (ICD-10 C61; ICD-O-3 C619)cdc-uscsObserved
3Malignant Pancreatic NeoplasmCancer21,899—observed#3 of 26USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259)cdc-uscsObserved
4Malignant Colon NeoplasmCancer21,568—observed#4 of 26USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260)cdc-uscsObserved
5Malignant Liver NeoplasmCancer17,843—observed#5 of 26USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221)cdc-uscsObserved
6LeukemiaCancer Family13,360—observed#6 of 26USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode)cdc-uscsObserved
7Malignant Esophageal NeoplasmCancer12,317—observed#7 of 26USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159)cdc-uscsObserved
8Malignant Bladder NeoplasmCancer11,941—observed#8 of 26USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679)cdc-uscsObserved
9Non-Hodgkin LymphomaHematologic Malignancy11,300—observed#9 of 26USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood))cdc-uscsObserved
10Malignant Central Nervous System NeoplasmCancer9,510—observed#10 of 26USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729)cdc-uscsObserved
11Malignant Kidney NeoplasmCancer8,996—observed#11 of 26USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659)cdc-uscsObserved
12Malignant Gastric NeoplasmCancer6,845—observed#12 of 26USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169)cdc-uscsObserved
13Multiple MyelomaHematologic Malignancy6,734—observed#13 of 26USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734)cdc-uscsObserved
14Malignant Rectal NeoplasmCancer6,074—observed#14 of 26USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209)cdc-uscsObserved
15Cutaneous MelanomaCancer5,425—observed#15 of 26USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790)cdc-uscsObserved
16Malignant Laryngeal NeoplasmCancer3,048—observed#16 of 26USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329)cdc-uscsObserved
17Malignant MesotheliomaCancer Family1,972—observed#17 of 26USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site))cdc-uscsObserved
18Malignant Thyroid Gland NeoplasmCancer926—observed#18 of 26USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739)cdc-uscsObserved
19Malignant Salivary Gland NeoplasmCancer653—observed#19 of 26USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089)cdc-uscsObserved
20Hodgkin LymphomaHematologic Malignancy579—observed#20 of 26USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal))cdc-uscsObserved
21Malignant Nasopharyngeal NeoplasmCancer510—observed#21 of 26USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119)cdc-uscsObserved
22Malignant Breast NeoplasmCancer Family464—observed#22 of 26USCS "Male Breast" (ICD-10 C50; ICD-O-3 C500-C509)cdc-uscsObserved
23Malignant Testicular NeoplasmCancer431—observed#23 of 26USCS "Testis" (ICD-10 C62; ICD-O-3 C620-C629)cdc-uscsObserved
24Malignant Anal NeoplasmCancer427—observed#24 of 26USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218)cdc-uscsObserved
25Malignant Hypopharyngeal NeoplasmCancer322—observed#25 of 26USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139)cdc-uscsObserved
26Malignant Penile NeoplasmCancer317—observed#26 of 26USCS "Penis" (ICD-10 C60; ICD-O-3 C600-C609)cdc-uscsObserved
cdc-uscsProvenance
Source
U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
Dataset
U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
Version
USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
registry
License
US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
Run
ING-CDCUSCS-20260908-000001
Open at source Rank from snapshot geo=USA|sex=male|age=all|year=2016|level=top · full ranking and "Why this rank?"High confidencetrend ↓

Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)

Top cancers

By new cases

2016 · Male · all ages · 27 site groups

#CancerNew cases (count)95% CITypeRank in scopeSite definitionSource
1Malignant Prostate NeoplasmCancer207,883—observed#1 of 27USCS "Prostate" (ICD-10 C61; ICD-O-3 C619)cdc-uscsObserved
2Malignant Lung NeoplasmCancer117,545—observed#2 of 27USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349)cdc-uscsObserved
3Malignant Bladder NeoplasmCancer59,180—observed#3 of 27USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679)cdc-uscsObserved
4Malignant Colon NeoplasmCancer51,625—observed#4 of 27USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260)cdc-uscsObserved
5Cutaneous MelanomaCancer51,002—observed#5 of 27USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790)cdc-uscsObserved
6Malignant Kidney NeoplasmCancer42,549—observed#6 of 27USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659)cdc-uscsObserved
7Non-Hodgkin LymphomaHematologic Malignancy40,090—observed#7 of 27USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood))cdc-uscsObserved
8LeukemiaCancer Family32,440—observed#8 of 27USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode)cdc-uscsObserved
9Malignant Pancreatic NeoplasmCancer26,379—observed#9 of 27USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259)cdc-uscsObserved
10Malignant Liver NeoplasmCancer25,700—observed#10 of 27USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221)cdc-uscsObserved
11Malignant Rectal NeoplasmCancer24,858—observed#11 of 27USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209)cdc-uscsObserved
12Multiple MyelomaHematologic Malignancy15,932—observed#12 of 27USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734)cdc-uscsObserved
13Malignant Gastric NeoplasmCancer15,202—observed#13 of 27USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169)cdc-uscsObserved
14Malignant Esophageal NeoplasmCancer14,185—observed#14 of 27USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159)cdc-uscsObserved
15Malignant Central Nervous System NeoplasmCancer13,119—observed#15 of 27USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729)cdc-uscsObserved
16Malignant Thyroid Gland NeoplasmCancer12,802—observed#16 of 27USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739)cdc-uscsObserved
17Malignant Laryngeal NeoplasmCancer10,032—observed#17 of 27USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329)cdc-uscsObserved
18Malignant Testicular NeoplasmCancer9,204—observed#18 of 27USCS "Testis" (ICD-10 C62; ICD-O-3 C620-C629)cdc-uscsObserved
19Hodgkin LymphomaHematologic Malignancy4,837—observed#19 of 27USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal))cdc-uscsObserved
20Malignant Salivary Gland NeoplasmCancer2,813—observed#20 of 27USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089)cdc-uscsObserved
21Malignant Anal NeoplasmCancer2,734—observed#21 of 27USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218)cdc-uscsObserved
22Malignant MesotheliomaCancer Family2,433—observed#22 of 27USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site))cdc-uscsObserved
23Malignant Breast NeoplasmCancer Family2,130—observed#23 of 27USCS "Male Breast" (ICD-10 C50; ICD-O-3 C500-C509)cdc-uscsObserved
24Malignant Hypopharyngeal NeoplasmCancer1,875—observed#24 of 27USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139)cdc-uscsObserved
25Malignant Penile NeoplasmCancer1,560—observed#25 of 27USCS "Penis" (ICD-10 C60; ICD-O-3 C600-C609)cdc-uscsObserved
26Malignant Nasopharyngeal NeoplasmCancer1,401—observed#26 of 27USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119)cdc-uscsObserved
27Kaposi SarcomaCancer1,102—observed#27 of 27USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site))cdc-uscsObserved
cdc-uscsProvenance
Source
U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
Dataset
U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
Version
USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
registry
License
US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
Run
ING-CDCUSCS-20260908-000001
Open at source Rank from snapshot geo=USA|sex=male|age=all|year=2016|level=top · full ranking and "Why this rank?"High confidencetrend ↓

Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)

Top cancers

By mortality rate (age-standardized)

2016 · Male · all ages · 26 site groups · 2000 U.S. standard population (19 age groups)

#CancerMortality rate (age-standardized) (per 100,000)95% CITypeRank in scopeSite definitionSource
1Malignant Lung NeoplasmCancer47.547.2–47.9observed#1 of 26USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349)cdc-uscsObserved
2Malignant Prostate NeoplasmCancer2019.8–20.2observed#2 of 26USCS "Prostate" (ICD-10 C61; ICD-O-3 C619)cdc-uscsObserved
3Malignant Colon NeoplasmCancer1312.8–13.2observed#3 of 26USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260)cdc-uscsObserved
4Malignant Pancreatic NeoplasmCancer12.812.6–13observed#4 of 26USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259)cdc-uscsObserved
5Malignant Liver NeoplasmCancer9.79.6–9.9observed#5 of 26USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221)cdc-uscsObserved
6LeukemiaCancer Family8.48.3–8.6observed#6 of 26USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode)cdc-uscsObserved
7Malignant Bladder NeoplasmCancer7.77.6–7.9observed#7 of 26USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679)cdc-uscsObserved
8Malignant Esophageal NeoplasmCancer76.9–7.1observed#8 of 26USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159)cdc-uscsObserved
9Non-Hodgkin LymphomaHematologic Malignancy76.9–7.2observed#8 of 26USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood))cdc-uscsObserved
10Malignant Central Nervous System NeoplasmCancer5.55.4–5.6observed#10 of 26USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729)cdc-uscsObserved
11Malignant Kidney NeoplasmCancer5.35.2–5.4observed#11 of 26USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659)cdc-uscsObserved
12Malignant Gastric NeoplasmCancer4.14–4.2observed#12 of 26USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169)cdc-uscsObserved
13Multiple MyelomaHematologic Malignancy4.14–4.2observed#12 of 26USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734)cdc-uscsObserved
14Malignant Rectal NeoplasmCancer3.53.4–3.6observed#14 of 26USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209)cdc-uscsObserved
15Cutaneous MelanomaCancer3.33.2–3.4observed#15 of 26USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790)cdc-uscsObserved
16Malignant Laryngeal NeoplasmCancer1.71.6–1.8observed#16 of 26USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329)cdc-uscsObserved
17Malignant MesotheliomaCancer Family1.31.2–1.3observed#17 of 26USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site))cdc-uscsObserved
18Malignant Thyroid Gland NeoplasmCancer0.60.5–0.6observed#18 of 26USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739)cdc-uscsObserved
19Hodgkin LymphomaHematologic Malignancy0.40.3–0.4observed#19 of 26USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal))cdc-uscsObserved
20Malignant Salivary Gland NeoplasmCancer0.40.4–0.4observed#19 of 26USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089)cdc-uscsObserved
21Malignant Breast NeoplasmCancer Family0.30.2–0.3observed#21 of 26USCS "Male Breast" (ICD-10 C50; ICD-O-3 C500-C509)cdc-uscsObserved
22Malignant Nasopharyngeal NeoplasmCancer0.30.3–0.3observed#21 of 26USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119)cdc-uscsObserved
23Malignant Testicular NeoplasmCancer0.30.2–0.3observed#21 of 26USCS "Testis" (ICD-10 C62; ICD-O-3 C620-C629)cdc-uscsObserved
24Malignant Anal NeoplasmCancer0.20.2–0.3observed#24 of 26USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218)cdc-uscsObserved
25Malignant Hypopharyngeal NeoplasmCancer0.20.2–0.2observed#24 of 26USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139)cdc-uscsObserved
26Malignant Penile NeoplasmCancer0.20.2–0.2observed#24 of 26USCS "Penis" (ICD-10 C60; ICD-O-3 C600-C609)cdc-uscsObserved
cdc-uscsProvenance
Source
U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
Dataset
U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
Version
USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
registry
License
US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
Run
ING-CDCUSCS-20260908-000001
Open at source Rank from snapshot geo=USA|sex=male|age=all|year=2016|level=top · full ranking and "Why this rank?"High confidencetrend ↓

Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)

Top cancers

By incidence rate (age-standardized)

2016 · Male · all ages · 27 site groups · 2000 U.S. standard population (19 age groups)

#CancerIncidence rate (age-standardized) (per 100,000)95% CITypeRank in scopeSite definitionSource
1Malignant Prostate NeoplasmCancer109.9109.4–110.3observed#1 of 27USCS "Prostate" (ICD-10 C61; ICD-O-3 C619)cdc-uscsObserved
2Malignant Lung NeoplasmCancer67.567.1–67.9observed#2 of 27USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349)cdc-uscsObserved
3Malignant Bladder NeoplasmCancer35.635.3–35.8observed#3 of 27USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679)cdc-uscsObserved
4Malignant Colon NeoplasmCancer30.129.9–30.4observed#4 of 27USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260)cdc-uscsObserved
5Cutaneous MelanomaCancer29.929.6–30.2observed#5 of 27USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790)cdc-uscsObserved
6Malignant Kidney NeoplasmCancer2423.7–24.2observed#6 of 27USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659)cdc-uscsObserved
7Non-Hodgkin LymphomaHematologic Malignancy23.623.4–23.8observed#7 of 27USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood))cdc-uscsObserved
8LeukemiaCancer Family19.419.2–19.6observed#8 of 27USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode)cdc-uscsObserved
9Malignant Pancreatic NeoplasmCancer15.115–15.3observed#9 of 27USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259)cdc-uscsObserved
10Malignant Rectal NeoplasmCancer1413.8–14.2observed#10 of 27USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209)cdc-uscsObserved
11Malignant Liver NeoplasmCancer13.513.3–13.6observed#11 of 27USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221)cdc-uscsObserved
12Multiple MyelomaHematologic Malignancy9.29–9.3observed#12 of 27USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734)cdc-uscsObserved
13Malignant Gastric NeoplasmCancer8.88.7–9observed#13 of 27USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169)cdc-uscsObserved
14Malignant Esophageal NeoplasmCancer7.97.8–8observed#14 of 27USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159)cdc-uscsObserved
15Malignant Central Nervous System NeoplasmCancer7.77.6–7.9observed#15 of 27USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729)cdc-uscsObserved
16Malignant Thyroid Gland NeoplasmCancer7.57.4–7.6observed#16 of 27USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739)cdc-uscsObserved
17Malignant Testicular NeoplasmCancer5.95.8–6observed#17 of 27USCS "Testis" (ICD-10 C62; ICD-O-3 C620-C629)cdc-uscsObserved
18Malignant Laryngeal NeoplasmCancer5.55.4–5.6observed#18 of 27USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329)cdc-uscsObserved
19Hodgkin LymphomaHematologic Malignancy32.9–3observed#19 of 27USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal))cdc-uscsObserved
20Malignant Salivary Gland NeoplasmCancer1.71.6–1.8observed#20 of 27USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089)cdc-uscsObserved
21Malignant Anal NeoplasmCancer1.51.5–1.6observed#21 of 27USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218)cdc-uscsObserved
22Malignant MesotheliomaCancer Family1.51.5–1.6observed#21 of 27USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site))cdc-uscsObserved
23Malignant Breast NeoplasmCancer Family1.21.2–1.3observed#23 of 27USCS "Male Breast" (ICD-10 C50; ICD-O-3 C500-C509)cdc-uscsObserved
24Malignant Hypopharyngeal NeoplasmCancer11–1.1observed#24 of 27USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139)cdc-uscsObserved
25Malignant Penile NeoplasmCancer0.90.9–1observed#25 of 27USCS "Penis" (ICD-10 C60; ICD-O-3 C600-C609)cdc-uscsObserved
26Malignant Nasopharyngeal NeoplasmCancer0.80.7–0.8observed#26 of 27USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119)cdc-uscsObserved
27Kaposi SarcomaCancer0.70.6–0.7observed#27 of 27USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site))cdc-uscsObserved
cdc-uscsProvenance
Source
U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
Dataset
U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
Version
USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
registry
License
US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
Run
ING-CDCUSCS-20260908-000001
Open at source Rank from snapshot geo=USA|sex=male|age=all|year=2016|level=top · full ranking and "Why this rank?"High confidencetrend ↓

Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)

Trend

Mortality rate (age-standardized) — top 8 cancers, all years

Top cancers of 2016 (Male) traced over every year published for United States. Dashed lines mark estimated or projected values; the y axis starts at zero.

Mortality rate (age-standardized) by year for the top 8 cancers in United States016.633.349.966.583.2per 100,0001999200020052010201520202024Malignant Lung Neoplasm — 1999: 77Malignant Lung Neoplasm — 2000: 76.5Malignant Lung Neoplasm — 2001: 75.3Malignant Lung Neoplasm — 2002: 73.7Malignant Lung Neoplasm — 2003: 72Malignant Lung Neoplasm — 2004: 70.4Malignant Lung Neoplasm — 2005: 69.5Malignant Lung Neoplasm — 2006: 67.4Malignant Lung Neoplasm — 2007: 65.2Malignant Lung Neoplasm — 2008: 63.7Malignant Lung Neoplasm — 2009: 61.5Malignant Lung Neoplasm — 2010: 60.1Malignant Lung Neoplasm — 2011: 58Malignant Lung Neoplasm — 2012: 56.5Malignant Lung Neoplasm — 2013: 54.3Malignant Lung Neoplasm — 2014: 52.4Malignant Lung Neoplasm — 2015: 50.3Malignant Lung Neoplasm — 2016: 47.5Malignant Lung Neoplasm — 2017: 45.1Malignant Lung Neoplasm — 2018: 41.8Malignant Lung Neoplasm — 2018: 41.9Malignant Lung Neoplasm — 2019: 40.1Malignant Lung Neoplasm — 2019: 40.1Malignant Lung Neoplasm — 2020: 38.7Malignant Lung Neoplasm — 2020: 38.1Malignant Lung Neoplasm — 2021: 37.4Malignant Lung Neoplasm — 2021: 37.3Malignant Lung Neoplasm — 2022: 35.3Malignant Lung Neoplasm — 2022: 35.2Malignant Lung Neoplasm — 2023: 33.9Malignant Lung Neoplasm — 2023: 34.1Malignant Lung Neoplasm — 2024: 32.2Malignant Lung Neoplasm — 2024: 32.3Malignant Prostate Neoplasm — 1999: 31.6Malignant Prostate Neoplasm — 2000: 30.4Malignant Prostate Neoplasm — 2001: 29.5Malignant Prostate Neoplasm — 2002: 28.7Malignant Prostate Neoplasm — 2003: 27.2Malignant Prostate Neoplasm — 2004: 26.2Malignant Prostate Neoplasm — 2005: 25.4Malignant Prostate Neoplasm — 2006: 24.2Malignant Prostate Neoplasm — 2007: 24.2Malignant Prostate Neoplasm — 2008: 23Malignant Prostate Neoplasm — 2009: 22.1Malignant Prostate Neoplasm — 2010: 21.8Malignant Prostate Neoplasm — 2011: 20.9Malignant Prostate Neoplasm — 2012: 19.8Malignant Prostate Neoplasm — 2013: 19.6Malignant Prostate Neoplasm — 2014: 19.5Malignant Prostate Neoplasm — 2015: 19.4Malignant Prostate Neoplasm — 2016: 20Malignant Prostate Neoplasm — 2017: 19.5Malignant Prostate Neoplasm — 2018: 18.8Malignant Prostate Neoplasm — 2018: 18.9Malignant Prostate Neoplasm — 2019: 18.3Malignant Prostate Neoplasm — 2019: 18.4Malignant Prostate Neoplasm — 2020: 18.5Malignant Prostate Neoplasm — 2020: 19.4Malignant Prostate Neoplasm — 2021: 19Malignant Prostate Neoplasm — 2021: 19Malignant Prostate Neoplasm — 2022: 18.9Malignant Prostate Neoplasm — 2022: 18.6Malignant Prostate Neoplasm — 2023: 18.5Malignant Prostate Neoplasm — 2023: 18.5Malignant Prostate Neoplasm — 2024: 18.2Malignant Prostate Neoplasm — 2024: 18.3Malignant Pancreatic Neoplasm — 1999: 12.3Malignant Pancreatic Neoplasm — 2000: 12.1Malignant Pancreatic Neoplasm — 2001: 12.2Malignant Pancreatic Neoplasm — 2002: 12.2Malignant Pancreatic Neoplasm — 2003: 12.1Malignant Pancreatic Neoplasm — 2004: 12.4Malignant Pancreatic Neoplasm — 2005: 12.4Malignant Pancreatic Neoplasm — 2006: 12.4Malignant Pancreatic Neoplasm — 2007: 12.6Malignant Pancreatic Neoplasm — 2008: 12.5Malignant Pancreatic Neoplasm — 2009: 12.4Malignant Pancreatic Neoplasm — 2010: 12.7Malignant Pancreatic Neoplasm — 2011: 12.5Malignant Pancreatic Neoplasm — 2012: 12.7Malignant Pancreatic Neoplasm — 2013: 12.5Malignant Pancreatic Neoplasm — 2014: 12.7Malignant Pancreatic Neoplasm — 2015: 12.8Malignant Pancreatic Neoplasm — 2016: 12.8Malignant Pancreatic Neoplasm — 2017: 13.1Malignant Pancreatic Neoplasm — 2018: 12.7Malignant Pancreatic Neoplasm — 2018: 12.7Malignant Pancreatic Neoplasm — 2019: 12.7Malignant Pancreatic Neoplasm — 2019: 12.7Malignant Pancreatic Neoplasm — 2020: 12.9Malignant Pancreatic Neoplasm — 2020: 12.7Malignant Pancreatic Neoplasm — 2021: 13Malignant Pancreatic Neoplasm — 2021: 13Malignant Pancreatic Neoplasm — 2022: 12.9Malignant Pancreatic Neoplasm — 2022: 12.9Malignant Pancreatic Neoplasm — 2023: 12.7Malignant Pancreatic Neoplasm — 2023: 12.8Malignant Pancreatic Neoplasm — 2024: 12.9Malignant Pancreatic Neoplasm — 2024: 12.9Malignant Colon Neoplasm — 1999: 21.6Malignant Colon Neoplasm — 2000: 21.1Malignant Colon Neoplasm — 2001: 20.4Malignant Colon Neoplasm — 2002: 20.1Malignant Colon Neoplasm — 2003: 19.4Malignant Colon Neoplasm — 2004: 18Malignant Colon Neoplasm — 2005: 17.5Malignant Colon Neoplasm — 2006: 17Malignant Colon Neoplasm — 2007: 16.6Malignant Colon Neoplasm — 2008: 16Malignant Colon Neoplasm — 2009: 15.4Malignant Colon Neoplasm — 2010: 15Malignant Colon Neoplasm — 2011: 14.5Malignant Colon Neoplasm — 2012: 14.2Malignant Colon Neoplasm — 2013: 13.9Malignant Colon Neoplasm — 2014: 13.6Malignant Colon Neoplasm — 2015: 13.4Malignant Colon Neoplasm — 2016: 13Malignant Colon Neoplasm — 2017: 12.7Malignant Colon Neoplasm — 2018: 12.2Malignant Colon Neoplasm — 2018: 12.3Malignant Colon Neoplasm — 2019: 11.7Malignant Colon Neoplasm — 2019: 11.6Malignant Colon Neoplasm — 2020: 11.8Malignant Colon Neoplasm — 2020: 11.5Malignant Colon Neoplasm — 2021: 11.5Malignant Colon Neoplasm — 2021: 11.5Malignant Colon Neoplasm — 2022: 11.1Malignant Colon Neoplasm — 2022: 11.2Malignant Colon Neoplasm — 2023: 11.1Malignant Colon Neoplasm — 2023: 11.1Malignant Colon Neoplasm — 2024: 10.8Malignant Colon Neoplasm — 2024: 10.8Malignant Liver Neoplasm — 1999: 6.5Malignant Liver Neoplasm — 2000: 6.8Malignant Liver Neoplasm — 2001: 6.9Malignant Liver Neoplasm — 2002: 7.2Malignant Liver Neoplasm — 2003: 7.4Malignant Liver Neoplasm — 2004: 7.4Malignant Liver Neoplasm — 2005: 7.8Malignant Liver Neoplasm — 2006: 7.7Malignant Liver Neoplasm — 2007: 7.9Malignant Liver Neoplasm — 2008: 8.3Malignant Liver Neoplasm — 2009: 8.6Malignant Liver Neoplasm — 2010: 8.7Malignant Liver Neoplasm — 2011: 9.1Malignant Liver Neoplasm — 2012: 9.4Malignant Liver Neoplasm — 2013: 9.6Malignant Liver Neoplasm — 2014: 9.5Malignant Liver Neoplasm — 2015: 9.7Malignant Liver Neoplasm — 2016: 9.7Malignant Liver Neoplasm — 2017: 9.8Malignant Liver Neoplasm — 2018: 9.7Malignant Liver Neoplasm — 2018: 9.7Malignant Liver Neoplasm — 2019: 9.5Malignant Liver Neoplasm — 2019: 9.6Malignant Liver Neoplasm — 2020: 9.4Malignant Liver Neoplasm — 2020: 9.4Malignant Liver Neoplasm — 2021: 9.4Malignant Liver Neoplasm — 2021: 9.4Malignant Liver Neoplasm — 2022: 9.2Malignant Liver Neoplasm — 2022: 9.3Malignant Liver Neoplasm — 2023: 9.3Malignant Liver Neoplasm — 2023: 9.3Malignant Liver Neoplasm — 2024: 9.3Malignant Liver Neoplasm — 2024: 9.3Leukemia — 1999: 10.2Leukemia — 2000: 10.3Leukemia — 2001: 10.2Leukemia — 2002: 10.2Leukemia — 2003: 10Leukemia — 2004: 9.8Leukemia — 2005: 9.8Leukemia — 2006: 9.7Leukemia — 2007: 9.5Leukemia — 2008: 9.5Leukemia — 2009: 9.5Leukemia — 2010: 9.3Leukemia — 2011: 9.3Leukemia — 2012: 9.3Leukemia — 2013: 9.2Leukemia — 2014: 8.9Leukemia — 2015: 8.6Leukemia — 2016: 8.4Leukemia — 2017: 8.4Leukemia — 2018: 8.1Leukemia — 2018: 8Leukemia — 2019: 7.7Leukemia — 2019: 7.8Leukemia — 2020: 8Leukemia — 2020: 7.6Leukemia — 2021: 7.7Leukemia — 2021: 7.7Leukemia — 2022: 7.4Leukemia — 2022: 7.5Leukemia — 2023: 7.4Leukemia — 2023: 7.4Leukemia — 2024: 7.2Leukemia — 2024: 7.3Malignant Bladder Neoplasm — 1999: 7.7Malignant Bladder Neoplasm — 2000: 7.6Malignant Bladder Neoplasm — 2001: 7.6Malignant Bladder Neoplasm — 2002: 7.6Malignant Bladder Neoplasm — 2003: 7.5Malignant Bladder Neoplasm — 2004: 7.7Malignant Bladder Neoplasm — 2005: 7.7Malignant Bladder Neoplasm — 2006: 7.7Malignant Bladder Neoplasm — 2007: 7.7Malignant Bladder Neoplasm — 2008: 7.6Malignant Bladder Neoplasm — 2009: 7.7Malignant Bladder Neoplasm — 2010: 7.7Malignant Bladder Neoplasm — 2011: 7.7Malignant Bladder Neoplasm — 2012: 7.7Malignant Bladder Neoplasm — 2013: 7.8Malignant Bladder Neoplasm — 2014: 7.7Malignant Bladder Neoplasm — 2015: 7.7Malignant Bladder Neoplasm — 2016: 7.7Malignant Bladder Neoplasm — 2017: 7.5Malignant Bladder Neoplasm — 2018: 7.1Malignant Bladder Neoplasm — 2018: 7.1Malignant Bladder Neoplasm — 2019: 7Malignant Bladder Neoplasm — 2019: 7Malignant Bladder Neoplasm — 2020: 6.8Malignant Bladder Neoplasm — 2020: 7.2Malignant Bladder Neoplasm — 2021: 7.1Malignant Bladder Neoplasm — 2021: 7.1Malignant Bladder Neoplasm — 2022: 7.1Malignant Bladder Neoplasm — 2022: 6.9Malignant Bladder Neoplasm — 2023: 6.8Malignant Bladder Neoplasm — 2023: 6.8Malignant Bladder Neoplasm — 2024: 6.6Malignant Bladder Neoplasm — 2024: 6.7Malignant Esophageal Neoplasm — 1999: 7.7Malignant Esophageal Neoplasm — 2000: 7.7Malignant Esophageal Neoplasm — 2001: 7.9Malignant Esophageal Neoplasm — 2002: 7.8Malignant Esophageal Neoplasm — 2003: 7.7Malignant Esophageal Neoplasm — 2004: 7.7Malignant Esophageal Neoplasm — 2005: 7.9Malignant Esophageal Neoplasm — 2006: 7.8Malignant Esophageal Neoplasm — 2007: 7.7Malignant Esophageal Neoplasm — 2008: 7.5Malignant Esophageal Neoplasm — 2009: 7.5Malignant Esophageal Neoplasm — 2010: 7.5Malignant Esophageal Neoplasm — 2011: 7.4Malignant Esophageal Neoplasm — 2012: 7.3Malignant Esophageal Neoplasm — 2013: 7.2Malignant Esophageal Neoplasm — 2014: 7.1Malignant Esophageal Neoplasm — 2015: 7.1Malignant Esophageal Neoplasm — 2016: 7Malignant Esophageal Neoplasm — 2017: 6.8Malignant Esophageal Neoplasm — 2018: 6.6Malignant Esophageal Neoplasm — 2018: 6.6Malignant Esophageal Neoplasm — 2019: 6.8Malignant Esophageal Neoplasm — 2019: 6.8Malignant Esophageal Neoplasm — 2020: 6.5Malignant Esophageal Neoplasm — 2020: 6.4Malignant Esophageal Neoplasm — 2021: 6.4Malignant Esophageal Neoplasm — 2021: 6.4Malignant Esophageal Neoplasm — 2022: 6.4Malignant Esophageal Neoplasm — 2022: 6.4Malignant Esophageal Neoplasm — 2023: 6.3Malignant Esophageal Neoplasm — 2023: 6.3Malignant Esophageal Neoplasm — 2024: 6.2Malignant Esophageal Neoplasm — 2024: 6.3
Malignant Lung Neoplasm32.3 (2024)Malignant Prostate Neoplasm18.3 (2024)Malignant Pancreatic Neoplasm12.9 (2024)Malignant Colon Neoplasm10.8 (2024)Malignant Liver Neoplasm9.3 (2024)Leukemia7.3 (2024)Malignant Bladder Neoplasm6.7 (2024)Malignant Esophageal Neoplasm6.3 (2024)

cdc-uscsObservedstandard: 2000 U.S. standard population (19 age groups)264 points

Clinical research

Clinical trial activity in United States

Registrant-entered study locations on ClinicalTrials.gov mapped to this country (any study type, any phase). A site is one location; a multi-site study weighs by its number of sites. Recruiting = location status RECRUITING, or the study status when the site has none.

Trial map →
Sites
609,751
Studies with a site here
50,884
Recruiting sites
71,552
Recruiting studies
7,740
Top-level cancers by sites in United States (descendants included)
CancerSitesStudiesRecruiting studiesShare of sites
Malignant Lung Neoplasm83,3974,58273913.7%
Malignant Breast Neoplasm81,6515,55282513.4%
Leukemia51,3984,6596458.4%
Non-Hodgkin Lymphoma46,7474,3346807.7%
Malignant Prostate Neoplasm35,4943,2265425.8%
Malignant Ovarian Neoplasm28,3171,6732574.6%
Malignant Uterine Corpus Neoplasm22,5048381833.7%
Malignant Kidney Neoplasm22,2501,2131693.6%
Malignant Pancreatic Neoplasm20,3701,8123213.3%
Malignant Cervical Neoplasm19,3788301443.2%
Multiple Myeloma18,6421,8792593.1%
Malignant Central Nervous System Neoplasm18,6331,6943023.1%
Malignant Bladder Neoplasm14,6597531502.4%
Malignant Liver Neoplasm12,9021,1871922.1%
Malignant Esophageal Neoplasm11,3686711531.9%
Malignant Gastric Neoplasm10,8317001471.8%
Malignant Colon Neoplasm8,850561621.5%
Malignant Rectal Neoplasm8,089436701.3%
Cutaneous Melanoma7,096165271.2%
Hodgkin Lymphoma5,597647740.9%
Malignant Oropharyngeal Neoplasm4,995297640.8%
Skin Carcinoma4,965232520.8%
Malignant Thyroid Gland Neoplasm4,053301600.7%
Malignant Lip and Oral Cavity Neoplasm4,048228490.7%
Malignant Laryngeal Neoplasm3,712164310.6%
By phase (a Phase II/III study counts in both)
PhaseSitesStudiesRecruiting
Phase 180,06916,1012,353
Phase 2255,71319,5802,684
Phase 3247,9964,036558
Phase 43,751591100

Computed formula ci-trial-sites-v1 · source: clinicaltrials · shares are of sites, not of studies

Data updated 16 hours agoSource updated unknowntrial_site_country_counts

Regulatory

Oncology approval records · US

Records of the country's regulator as ingested (one record = one decision for one application or product identifier). Absence of a record here is not evidence of absence.

All records →

FDA · approved: 2,343 records / 304 drugs

  • Sep 18, 2026Abemaciclib approved cancer not stated in this recordEfficacy supplement 2026-09-18 (see label)openfda
  • Sep 9, 2026Aminolevulinic Acid approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
  • Sep 9, 2026Sevabertinib approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
  • Sep 4, 2026Camizestrant approved Malignant Breast Neoplasmin combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor…openfda
  • Aug 28, 2026Ropeginterferon Alfa-2b approved cancer not stated in this recordEfficacy supplement 2026-08-28 (see label)openfda
  • Aug 25, 2026Zanidatamab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
  • Aug 25, 2026Tislelizumab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
  • Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
  • Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
  • Jul 14, 2026Selpercatinib approved cancer not stated in this recordEfficacy supplement 2026-07-14 (see label)openfda

Regulatory

Provenance

Sources and freshness

What each source covers for this geography, exactly as ingested. Values are normalized (units, labels) but never changed.

SourceMetricSexYearsCancersEstimate typesStandard populationIngested
cdc-uscsIncidence rate (age-standardized)Both1999–2023 (25)24observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-uscsIncidence rate (age-standardized)Female1999–2023 (25)29observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-uscsIncidence rate (age-standardized)Male1999–2023 (25)27observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-uscsMortality rate (age-standardized)Both1999–2024 (26)23observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-wonderMortality rate (age-standardized)Both2018–2024 (7)36observed2000 U.S. Std. Population2026-09-08
cdc-uscsMortality rate (age-standardized)Female1999–2024 (26)28observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-wonderMortality rate (age-standardized)Female2018–2024 (7)36observed2000 U.S. Std. Population2026-09-08
cdc-uscsMortality rate (age-standardized)Male1999–2024 (26)26observed2000 U.S. standard population (19 age groups)2026-09-08
cdc-wonderMortality rate (age-standardized)Male2018–2024 (7)36observed2000 U.S. Std. Population2026-09-08
cdc-uscsNew casesBoth1999–2023 (25)32observed—2026-09-08
cdc-uscsNew casesFemale1999–2023 (25)29observed—2026-09-08
cdc-uscsNew casesMale1999–2023 (25)27observed—2026-09-08
cdc-uscsDeathsBoth1999–2024 (26)31observed—2026-09-08
cdc-wonderDeathsBoth2018–2024 (7)36observed—2026-09-08
cdc-uscsDeathsFemale1999–2024 (26)28observed—2026-09-08
cdc-wonderDeathsFemale2018–2024 (7)36observed—2026-09-08
cdc-uscsDeathsMale1999–2024 (26)26observed—2026-09-08
cdc-wonderDeathsMale2018–2024 (7)36observed—2026-09-08
cdc-wonderMortality rate (crude)Both2018–2024 (7)36observed—2026-09-08
cdc-wonderMortality rate (crude)Female2018–2024 (7)36observed—2026-09-08
cdc-wonderMortality rate (crude)Male2018–2024 (7)36observed—2026-09-08

Age-standardized rates use the 2000 U.S. standard population (19 age groups); they are not comparable with rates standardized to the World (Segi) population used by IARC. Global comparisons are not available: the IARC Global Cancer Observatory remains under license review and the SEER API awaits credentials (CLAUDE.md §10.3-10.4). Only geographies with licensed observations get a page; see /countries.

Data updated 22 days agoSource updated 1999–202410,680 observations approx. · ranks from snapshots geo=USA